Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $21,547.50 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 6,375 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $3.38, for a total transaction of $21,547.50. Following the completion of the transaction, the chief executive officer owned 343,999 shares of the company’s stock, valued at $1,162,716.62. This trade represents a 1.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Fred Aslan also recently made the following trade(s):

• On Friday, October 17th, Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $6.00, for a total value of $153,000.00.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV traded up $0.26 during trading hours on Monday, reaching $3.51. 169,554 shares of the company’s stock traded hands, compared to its average volume of 537,320. Artiva Biotherapeutics, Inc. has a 52-week low of $1.47 and a 52-week high of $13.19. The firm has a 50-day simple moving average of $3.38 and a 200 day simple moving average of $2.70. The firm has a market cap of $86.17 million, a PE ratio of -1.34 and a beta of 3.04.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. Sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently made changes to their positions in ARTV. Charles Schwab Investment Management Inc. grew its stake in shares of Artiva Biotherapeutics by 26.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after buying an additional 11,355 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $48,000. Nuveen LLC purchased a new position in shares of Artiva Biotherapeutics in the 1st quarter worth approximately $144,000. Ground Swell Capital LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $38,000. Finally, Citadel Advisors LLC raised its holdings in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ARTV shares. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, October 17th. HC Wainwright upped their price target on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. Finally, Wedbush boosted their target price on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.